Member Info for Hemo

I think given the importance of what is going on with Illumina just having a CMC is material so they should update us on its purpose and outcome.

Is that on public record notaflipper?

How bl00dy long does it take to negotiate a settlement with Illumina? I really don’t think they want to settle so what should we do? Carry on as we are and wait for the appeal? Withdraw from the UK market unilaterally? This impasse is so frustrating it’s like Chinese torture. Who will blink first?

Forgive if already asked and answered but could acceptance of the submission come quicker than the suggested two months given it has been a rolling submission for the last couple of months? Thanks

Who is Stephen Myers? Does anyone know?

Is that right? Will certainly have to be disclosed. Maybe it’s Goldfields!

Earlier than I predicted but at least it’s out of the way now and we have some confidence in our cash position.

£0.2m of cash and £0.2m of liabilities so effectively no cash. This will either have to be sold quickly or cash raised. Some clarity from the Board would have helped or it’s all just speculation.

I’m afraid I disagree. Net current assets at 31/12/17 zero. Cash raised since year end c.£0.9m (£0.55m equity after costs and £0.35m disposal of Choco). Likely costs to date 2018 c.£0.3m. Rough cash estimate £0.6m. Tell me if I’ve missed anything. Only thing I can think of is option payment of £0.2m early Jan that would make things worse. Happy to be proved wrong.

It would be helpful to know how much cash we have now and how much we plan to spend. By my rough calculations we probably have about �0.5m-�0.6m in the bank, which I think means another capital raise shortly that is probably why the share price is not rising after the good news on the Mankayan licence.

Bill increased his %, Alan’s decreased

How do you know that prickly? Is it on his FB page?!

Just the outcome of this week's placing

Finals won’t be out until end September I bet because they changed the year end to December?

Sorry flipper, finals not due until end September?

Why does Winnifrith get to take part? It really does stick in the craw and should have been rejected by the Board if they had any sense and wanted to avoid accusations of cronyism and unfairness.

Great to see break-even achieved. Pleased to learn Denman is leaving thereby saving �140k per annum. Would have liked to hear more about gross margin achieved, Brazil roll-out and Genoma debt. Glad we have not exited the UK yet and seem to be more engaged in looking for a settlement with Illumina. I still think we should get the court to impose a settlement, stay in the UK and pay 10% licence fee. Disappointed that directors are getting to buy at 4.5p, wish it had been higher so they share more of our pain. Certainly leaves a bitter aftertaste. Intrigued to know what 'adapting the product development roadmap' means and its implications. Sounds like a new product is imminent. H2 growth vs H1 was 30%, which suggests a slight slowdown to me because FY growth was 35%? Who are our new lawyers? Kenya and India sound positive but still no impact on the share price until the litigation is resolved.

Would have been nice to know how much money we have left and how much it will cost to do the further work they are proposing on Mankayan and Eureka. Don’t much fancy any further acquisitions right now!

Don’t Roche offer the SAFE test? If so won’t they also have to come to an agreement with Illumina to continue offering this in the UK?

That’s fine but then tell us when it will be. It’s all about communication.